Ruboxistaurin (proposed brand name Arxxant) is an investigational drug for diabetic peripheral retinopathy. It is being investigated by Eli Lilly and Company.On February 2006 Lilly submitted a New Drug Application for ruboxistaurin and on August 18 2006 Lilly received an approvable letter from the United States Food and Drug Administration for ruboxistaurin with a request for an additional clinical trial which would take 5 years to complete.
This page contains content from the copyrighted Wikipedia article "Ruboxistaurin"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
